LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results LAVA-051 shows encouraging initial safety and pharmacodynamic observations; on track for more dose escalation data from Phase 1/2a trial in Q2 2022LAVA-1207 Phase 1/2a trial in mCRPC on track to...

LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2022 LAVA-051 preliminary data shows encouraging initial clinical safety; no dose-limiting toxicity or cytokine release syndromePharmacodynamic markers indicate increasing receptor occupancy with...

LAVA Therapeutics Presents Preclinical Data on its Gammabody™ T Cell Engager Platform at the 21st Annual PepTalk Conference The collective data indicate that LAVA’s approach to recruit gamma delta T cells with its bispecific antibody platform results in potent anti-tumor activity while avoiding off-tumor toxicity and...